(Q35665113)

9 August 2017

title

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours (English)

1 reference

9 August 2017

1 reference

0 references

0 references

Anna Koumarianou

1

1 reference

9 August 2017

Stavroula Antoniou

2

1 reference

9 August 2017

George Kanakis

3

1 reference

9 August 2017

Nikolaos Economopoulos

4

1 reference

9 August 2017

Dimitra Rontogianni

5

1 reference

9 August 2017

Anastasios Ntavatzikos

6

1 reference

9 August 2017

Nikolaos Tsavaris

7

1 reference

9 August 2017

Dimitrios Pectasides

8

1 reference

9 August 2017

George Dimitriadis

9

1 reference

9 August 2017

Gregory Kaltsas

10

1 reference

9 August 2017

publication date

9 January 2012

1 reference

9 August 2017

published in

Endocrine-Related Cancer

1 reference

9 August 2017

volume

19

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

L1-4

1 reference

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255566

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255566

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255566

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255566

Gastroenteropancreatic neuroendocrine tumours

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255566

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255566

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255566

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255566

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255566

Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22232542

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22232542

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1530/ERC-11-0287

1 reference

9 August 2017

1 reference

9 August 2017

1 reference